Litcius/Paper detail

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial

Sandro Pignata, Domenica Lorusso, Florence Joly, Ciro Gallo, Nicoletta Colombo, Cristiana Sessa, Aristotelis Bamias, Vanda Salutari, Frédèric Selle, Simona Frezzini, Ugo De Giorgi, Patricia Pautier, Alessandra Bologna, Michele Orditura, Coraline Dubot, Angiolo Gadducci, Serafina Mammoliti, Isabelle Ray‐Coquard, Elena Zafarana, Enrico Breda, Laure Favier, Antonio Ardizzoia, Saverio Cinieri, Rémy Largillier, Daniela Sambataro, Emmanuel Guardiola, Rossella Lauria, Carmela Pisano, Francesco Raspagliesi, Giovanni Scambia, Gennaro Daniele, Francesco Perrone, Sandro Pignata, Domenica Lorusso, Florence Joly, Ciro Gallo, Nicoletta Colombo, Cristiana Sessa, Aristotelis Bamias, Vanda Salutari, Frédèric Selle, Simona Frezzini, Ugo De Giorgi, Patricia Pautier, Alessandra Bologna, Michele Orditura, C. Dubot, Angiolo Gadducci, Serafina Mammoliti, I. L. Ray-Coquard, Elena Zafarana, Enrico Breda, Laure Favier, Antonio Ardizzoia, Saverio Cinieri, R. Largillier, Daniela Sambataro, Emmanuel Guardiola, Rossella Lauria, Carmela Pisano, Francesco Raspagliesi, Giovanni Scambia, Gennaro Daniele, Francesco Perrone

2021The Lancet Oncology149 citationsDOI

Topics & Concepts

CarboplatinMedicineBevacizumabGemcitabineInternal medicineOvarian cancerOncologyPaclitaxelChemotherapySurgeryUrologyCancerCisplatinOvarian cancer diagnosis and treatmentPARP inhibition in cancer therapyAngiogenesis and VEGF in Cancer